v3.25.1
Long-Term Investments - Schedule of Ownership Percentages of Each Investee (Details)
 3 Months Ended
Mar. 31, 2025
Dec. 31, 2024
Braingenesis Biotechnology Co., Ltd. [Member]    
Schedule of Ownership Percentages of Each Investee [Line Items]    
Ownership percentage [1] 0.17% 0.17%
Accounting treatments [1] Cost Method  
Genepharm Biotech Corporation [Member]    
Schedule of Ownership Percentages of Each Investee [Line Items]    
Ownership percentage 0.67% 0.67%
Accounting treatments Cost Method  
BioHopeKing Corporation [Member]    
Schedule of Ownership Percentages of Each Investee [Line Items]    
Ownership percentage 5.90% 5.90%
Accounting treatments Cost Method  
ForSeeCon Eye Corporation [Member]    
Schedule of Ownership Percentages of Each Investee [Line Items]    
Ownership percentage 19.78% 19.78%
Accounting treatments Cost Method  
BioFirst Corporation [Member]    
Schedule of Ownership Percentages of Each Investee [Line Items]    
Ownership percentage 18.68% 18.68%
Accounting treatments Equity Method  
OncoX BioPharma, Inc. [Member]    
Schedule of Ownership Percentages of Each Investee [Line Items]    
Ownership percentage 24.97% 24.97%
Accounting treatments Equity Method  
Rgene Corporation [Member]    
Schedule of Ownership Percentages of Each Investee [Line Items]    
Ownership percentage 37.00% 26.65%
Accounting treatments Equity Method  
BioLite Japan K.K. [Member]    
Schedule of Ownership Percentages of Each Investee [Line Items]    
Ownership percentage 49.00% 49.00%
Accounting treatments Equity Method  
[1] This company was acquired by Canal Biotech Corporation Inc. Our stock is in the process of replacement with the stock of the acquired company and the ownership percentage is subject to change.